search
Back to results

Ultrasound-guided Femoral Puncture to Reduce Access- Related Complications After TAVR: (ACCESS-TAVR SIRIO)

Primary Purpose

Transcatheter Aortic Valve Replacement

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
US-guided femoral puncture vs Fluoroscopy-guided puncture
Sponsored by
Fondazione Toscana Gabriele Monasterio
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Transcatheter Aortic Valve Replacement

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Eligible Patients are male or female with severe aortic stenosis evaluated by the Heart Team as candidate to TAVR based on the current cardiology guidelines. Exclusion Criteria: Refusal to participate in the study; Inability to provide written consent to the study protocol; Chronic immuno-suppressant therapy; Any concomitant condition which, in the opinion of the Investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse, emotional/psychological disorder); Enrolment in another study that could confound the results of this study; Life expectancy < 1 year; Any contraindication to TAVR procedure; Non transfemoral TAVR.

Sites / Locations

  • Fondazione Toscana Gabriele MonasterioRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

US-guided femoral puncture

Fluoroscopy-guided puncture

Arm Description

US-guided femoral puncture and Perclose ProGlide/Prostyle implantation during transcatheter aortic valve replacement (TAVR)

Fluoroscopy-guided puncture and Perclose ProGlide/Prostyle implantation during transcatheter aortic valve replacement (TAVR)

Outcomes

Primary Outcome Measures

Composite of CV mortality, vascular complications or access-related bleeding after TAVR at 30 days.

Secondary Outcome Measures

CV mortality
Vascular complications
Life-threatening or disabling bleeding
Fatal bleeding (BARC type 5) OR Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) or Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b) OR Overt source of bleeding with drop in haemoglobin ≥5 g/dl or whole blood or packed red blood cells (RBCs) transfusion ≥4 units (BARC type 3b)
Major bleeding (BARC type 3a)
Overt bleeding either associated with a drop in the haemoglobin level of at least 3.0 g/dl or requiring transfusion of two or three units of whole blood/RBC, or causing hospitalization or permanent injury, or requiring surgery AND Does not meet criteria of life-threatening or disabling bleeding
Major vascular complications
Any aortic dissection, aortic rupture, annulus rupture, left ventricle perforation, or new apical aneurysm/pseudo-aneurysm OR Access site or access-related vascular injury (dissection, stenosis, perforation, rupture, arterio-venous fistula, pseudoaneurysm, haematoma, irreversible nerve injury, compartment syndrome, percutaneous closure device failure) leading to death, lifethreatening or major bleeding, visceral ischaemia, or neurological impairment OR Distal embolization (non-cerebral) from a vascular source requiring surgery or resulting in amputation or irreversible end-organ damage OR The use of unplanned endovascular or surgical intervention associated with death, major bleeding, visceral ischaemia or neurological impairment OR Any new ipsilateral lower extremity ischaemia documented by patient symptoms, physical exam, and/or decreased or absent blood flow on lower extremity angiogram OR Surgery for access siterelated nerve injury OR Permanent access site-related nerve injury
Minor vascular complications
Access site or access-related vascular injury (dissection, stenosis, perforation, rupture, arteriovenous fistula, pseudoaneurysms, haematomas, percutaneous closure device failure) not leading to death, life-threatening or major bleeding, visceral ischaemia, or neurological impairment OR Distal embolization treated with embolectomy and/or thrombectomy and not resulting in amputation or irreversible end-organ damage OR Any unplanned endovascularstenting or unplanned surgical intervention not meeting the criteria for a major vascular complication OR Vascular repair or the need for vascular repair (via surgery, ultrasound-guided compression, transcatheter embolization, or stent-graft) OR Percutaneous closure device failure of a closure device to achieve haemostasis at the arteriotomy site leading to alternative treatment (other than manual compression or adjunctive endovascular ballooning).

Full Information

First Posted
November 25, 2022
Last Updated
November 25, 2022
Sponsor
Fondazione Toscana Gabriele Monasterio
Collaborators
Nicolaus Copernicus University
search

1. Study Identification

Unique Protocol Identification Number
NCT05637983
Brief Title
Ultrasound-guided Femoral Puncture to Reduce Access- Related Complications After TAVR: (ACCESS-TAVR SIRIO)
Official Title
Ultrasound-guided Femoral Puncture to Reduce Access- Related Complications After TAVR: (ACCESS-TAVR SIRIO)
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 4, 2022 (Actual)
Primary Completion Date
November 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fondazione Toscana Gabriele Monasterio
Collaborators
Nicolaus Copernicus University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Recent observational data showed a marked reduction of vascular and bleeding complications by the use of ultrasound(US)-guided femoral artery puncture to gain the vascular access and guide the implantation of the Perclose ProGlide® vascular closure system. We aimed to compare in a 1:1 randomized fashion the effect of US-guided femoral puncture and Perclose ProGlide® implantation optimization vs fluoroscopy-guided puncture followed by Perclose ProGlide/ ProStyle implantation (standard approach) during TAVR.
Detailed Description
Transfemoral approach has become the standard route for a transcatheter aortic valve replacement (TAVR) procedure. Despite the technology improvements, vascular complications and access-related bleeding are frequently observed after TAVR and emerge predominantly within 30 days after TAVR. Recent observational data showed a marked reduction of vascular and bleeding complications by the use of ultrasound(US)- guided femoral artery puncture to gain the vascular access and guide the implantation of the Perclose ProGlide® vascular closure system. We aimed to compare in a 1:1 randomized fashion the effect of US-guided femoral puncture and Perclose ProGlide® implantation optimization vs fluoroscopy-guided puncture followed by Perclose ProGlide/ ProStyle implantation (standard approach) during TAVR.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Transcatheter Aortic Valve Replacement

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
1:1 randomized trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
508 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
US-guided femoral puncture
Arm Type
Experimental
Arm Description
US-guided femoral puncture and Perclose ProGlide/Prostyle implantation during transcatheter aortic valve replacement (TAVR)
Arm Title
Fluoroscopy-guided puncture
Arm Type
Active Comparator
Arm Description
Fluoroscopy-guided puncture and Perclose ProGlide/Prostyle implantation during transcatheter aortic valve replacement (TAVR)
Intervention Type
Procedure
Intervention Name(s)
US-guided femoral puncture vs Fluoroscopy-guided puncture
Intervention Description
US-guided femoral puncture and Perclose ProGlide®/Prostyle implantation compared to Fluoroscopy-guided puncture and Perclose ProGlide®/Prostyle in TAVR
Primary Outcome Measure Information:
Title
Composite of CV mortality, vascular complications or access-related bleeding after TAVR at 30 days.
Time Frame
1 month
Secondary Outcome Measure Information:
Title
CV mortality
Time Frame
1 month
Title
Vascular complications
Time Frame
1 month
Title
Life-threatening or disabling bleeding
Description
Fatal bleeding (BARC type 5) OR Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) or Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b) OR Overt source of bleeding with drop in haemoglobin ≥5 g/dl or whole blood or packed red blood cells (RBCs) transfusion ≥4 units (BARC type 3b)
Time Frame
1 month
Title
Major bleeding (BARC type 3a)
Description
Overt bleeding either associated with a drop in the haemoglobin level of at least 3.0 g/dl or requiring transfusion of two or three units of whole blood/RBC, or causing hospitalization or permanent injury, or requiring surgery AND Does not meet criteria of life-threatening or disabling bleeding
Time Frame
1 month
Title
Major vascular complications
Description
Any aortic dissection, aortic rupture, annulus rupture, left ventricle perforation, or new apical aneurysm/pseudo-aneurysm OR Access site or access-related vascular injury (dissection, stenosis, perforation, rupture, arterio-venous fistula, pseudoaneurysm, haematoma, irreversible nerve injury, compartment syndrome, percutaneous closure device failure) leading to death, lifethreatening or major bleeding, visceral ischaemia, or neurological impairment OR Distal embolization (non-cerebral) from a vascular source requiring surgery or resulting in amputation or irreversible end-organ damage OR The use of unplanned endovascular or surgical intervention associated with death, major bleeding, visceral ischaemia or neurological impairment OR Any new ipsilateral lower extremity ischaemia documented by patient symptoms, physical exam, and/or decreased or absent blood flow on lower extremity angiogram OR Surgery for access siterelated nerve injury OR Permanent access site-related nerve injury
Time Frame
1 month
Title
Minor vascular complications
Description
Access site or access-related vascular injury (dissection, stenosis, perforation, rupture, arteriovenous fistula, pseudoaneurysms, haematomas, percutaneous closure device failure) not leading to death, life-threatening or major bleeding, visceral ischaemia, or neurological impairment OR Distal embolization treated with embolectomy and/or thrombectomy and not resulting in amputation or irreversible end-organ damage OR Any unplanned endovascularstenting or unplanned surgical intervention not meeting the criteria for a major vascular complication OR Vascular repair or the need for vascular repair (via surgery, ultrasound-guided compression, transcatheter embolization, or stent-graft) OR Percutaneous closure device failure of a closure device to achieve haemostasis at the arteriotomy site leading to alternative treatment (other than manual compression or adjunctive endovascular ballooning).
Time Frame
1 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Eligible Patients are male or female with severe aortic stenosis evaluated by the Heart Team as candidate to TAVR based on the current cardiology guidelines. Exclusion Criteria: Refusal to participate in the study; Inability to provide written consent to the study protocol; Chronic immuno-suppressant therapy; Any concomitant condition which, in the opinion of the Investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse, emotional/psychological disorder); Enrolment in another study that could confound the results of this study; Life expectancy < 1 year; Any contraindication to TAVR procedure; Non transfemoral TAVR.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sergio Berti, MD
Phone
3488964831
Ext
+39
Email
berti@ftgm.it
First Name & Middle Initial & Last Name or Official Title & Degree
Eliano Navarese, MD
Phone
3342594725
Ext
+39
Email
elianonavarese@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sergio Berti, MD
Organizational Affiliation
Fondazione Toscana Gabriele Monasterio
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Eliano Navarese
Organizational Affiliation
Nicolaus Copernicus University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fondazione Toscana Gabriele Monasterio
City
Massa
State/Province
MS
ZIP/Postal Code
54100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sergio Berti, MD
Phone
0503152216
Ext
+39
Email
berti@ftgm.it
First Name & Middle Initial & Last Name & Degree
Nataliya Pylypiv
Phone
3891256513
Ext
+39
Email
pylypivn@ftgm.it
First Name & Middle Initial & Last Name & Degree
Anees Ali Ahmed Al Jabri, MD
First Name & Middle Initial & Last Name & Degree
Marcello Ravani, MD
First Name & Middle Initial & Last Name & Degree
Giuseppe Raffaele Trianni, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Ultrasound-guided Femoral Puncture to Reduce Access- Related Complications After TAVR: (ACCESS-TAVR SIRIO)

We'll reach out to this number within 24 hrs